It would be appropriate for the NEJM to publish an editorial response from the CAP or other pathology organization.

Aside from the statutory authority of the FDA, the article completely ignored the many arguments made by multiple pathologists and others that the FDA approach would have harmed patients by making testing unavailable due to increased costs without corresponding benefits.

Would they refer to the American Thoracic Society as the "trade organization representing pulmonologists"?